Clinical Trials Browser

Terminated × enzalutamide × Clear all

NCT03869762 2026-04-13

DICE

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT01885949 2026-02-24

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 7 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

Bites and Stings

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

9 enrolled 14 charts

Prostatic Neoplasms

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

Prostatic Neoplasms

NCT03177187 2024-09-26

ACE

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 3 Terminated

Prostate Cancer Metastatic

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04844749 2024-02-05

VERACITY

Phase 3 Terminated

Prostatic Neoplasms, Castration-Resistant

NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Terminated

Prostatic Neoplasms, Patient Preference

NCT04033328 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

Phase 1 Terminated

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Phase 2 Terminated

3 enrolled 9 charts

Prostatic Neoplasms

NCT04157088 2023-08-04

DaroAcT

Phase 2 Terminated

30 enrolled 25 charts

Prostatic Neoplasms, Castration-Resistant

NCT02640534 2023-06-27

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Phase 2 Terminated

Prostatic Neoplasms

NCT02438007 2023-03-15

ARMOR3-SV

Phase 3 Terminated

Prostatic Neoplasms

NCT04142060 2022-10-28

ARIANNA

Phase 2 Terminated

Breast Neoplasms

NCT04237584 2022-10-07

ESCALATE

Phase 3 Terminated

23 enrolled 11 charts

Metastatic Castration-resistant Prostate Cancer

NCT02457910 2022-08-22

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1/2 Terminated

30 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Phase 2 Terminated

4 enrolled 12 charts

Prostatic Neoplasms

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT02508636 2021-10-12

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

Phase 2 Terminated

11 enrolled 17 charts

Prostatic Neoplasms

NCT02885649 2021-09-16

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Phase EARLY_PHASE1 Terminated

Carcinoma, Renal Cell

NCT02489123 2021-08-10

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

8 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Phase 1 Terminated

Prostate Adenocarcinoma

NCT03478904 2021-05-10

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Phase 1 Terminated

1 enrolled 8 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02685267 2021-04-09

Doce/Enza

Phase 2 Terminated

9 enrolled 11 charts

Prostatic Neoplasms

NCT02607228 2020-12-08

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Phase 1/2 Terminated

31 enrolled 22 charts

Metastatic Castrate-Resistant Prostate Cancer

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Prostatic Neoplasms

NCT02500901 2019-10-21

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Phase 1 Terminated

2 enrolled 8 charts

Prostatic Neoplasms

NCT02379390 2019-06-21

PRIMCAB

Phase 2 Terminated

8 enrolled 8 charts

Prostate Cancer Metastatic

NCT02605863 2018-10-03

Enzalutamide for Bladder Cancer Chemoprevention

Phase 2 Terminated

1 enrolled 6 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02491411 2018-07-12

DEXTER

Phase NA Terminated

5 enrolled 5 charts

Prostatic Neoplasms

NCT02441517 2018-04-19

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Phase 4 Terminated

4 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms